Clinical Trial Update: An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

View source ↗

Summary

The document reports marketing approval of ibrutinib for relapsed or refractory mantle cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Janssen Biotech, Inc. | Conditions: Relapsed or Refractory Mantle Cell Lymphoma | Status: APPROVED_FOR_MARKETING